Network pharmacology: Anti-obesity and insulin-sensitizing effects of Danggui-Huangjing herb-pair via epidermal growth factor receptor/phosphatidylinositol 3-kinase/protein kinase B pathway

Figure 6 Danggui-Huangjing improves the phenotype and histology of obese C57BL/6 mice. A: Body mass curves (n = 6/group). Mice fed standard chow (normal control) or high-fat diet (45% fat, model control/Danggui/Huangjing/Danggui-Huangjing) for 18 weeks (induction: Weeks 1-10; treatment: Weeks 11-18); Danggui/Huangjing/Danggui-Huangjing: Intragastric administration (1.82 g/kg/day); B: Oral glucose tolerance testing results (n = 6/group). Fasted 12 hours, glucose (2 g/kg, oral gavage), blood glucose measured at 0/30/60/90/120 minutes, area under the curve (0-120) via trapezoidal rule; C-E: Body fat percentage (echo magnetic resonance imaging 100H), liver, and epididymal white adipose tissue masses (n = 6/group); F-I: Serum total cholesterol, triglyceride, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol (n = 6/group), measured by BS-420 analyzer with commercial kits. Data are presented as mean ± SD and were analyzed by one-way analysis of variance followed by the Bonferroni post hoc test. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs normal control group; ^dP < 0.05, ^eP < 0.01, ^fP < 0.001 vs model control group; ^gP < 0.05, ^hP < 0.01, ⁱP < 0.001 vs Danggui-Huangjing group. DG: Danggui; DH: Danggui-Huangjing; HDL: High-density lipoprotein; HJ: Huangjing; LDL: Low-density lipoprotein; MC: Model control; NC: Normal control; OGTT: Oral glucose tolerance testing; TC: Total cholesterol; TG: Triglyceride.